miRTARGET:一个集成的网络工具,用于鉴定在癌症中具有潜在治疗或预后价值的microRNA靶标

IF 7.7 2区 医学 Q1 Biochemistry, Genetics and Molecular Biology
Matjaz Rokavec , Heiko Hermeking
{"title":"miRTARGET:一个集成的网络工具,用于鉴定在癌症中具有潜在治疗或预后价值的microRNA靶标","authors":"Matjaz Rokavec ,&nbsp;Heiko Hermeking","doi":"10.1016/j.neo.2025.101202","DOIUrl":null,"url":null,"abstract":"<div><div>miRTARGET (<span><span>https://www.mirtarget.com</span><svg><path></path></svg></span>) is a web tool for the identification of miRNA targets. It integrates experimental miRNA-related datasets and computational algorithms to generate prediction scores for targets of 1744 human miRNAs. The score is based on four dataset categories: mRNA profiling in cells or mice after (1) ectopic miRNA expression or (2) miRNA inactivation by knock-out or knock-down, (3) correlation analyses of mRNA and miRNA expression profiles, and (4) ten computational miRNA target prediction algorithms. Our validation analyses demonstrated a significant enrichment of published/validated miRNA targets among the predicted miRNA targets, underlining the reliability of the miRTARGET prediction score. In addition, miRTARGET integrates cancer-related datasets from primary tumors and cell lines, allowing users to filter/extract miRNA targets based on cancer cell line dependency, survival associations, and differential expression between tumor and normal tissues across 32 cancer entities. As a proof-of-concept, miRTARGET identified <em>CDC7</em> and its regulatory unit <em>DBF4</em> as the top cancer-associated predicted targets of the tumor suppressive miRNA miR-30a. Therefore, the CDC7-DBF4 complex may represent an attractive candidate therapeutic target for the treatment of cancers with miR-30a inactivation. Altogether, miRTARGET is a powerful and user-friendly web tool for exploring miRNA targets with therapeutic or prognostic potential in cancer.</div></div>","PeriodicalId":18917,"journal":{"name":"Neoplasia","volume":"67 ","pages":"Article 101202"},"PeriodicalIF":7.7000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"miRTARGET: An integrated web tool for the identification of microRNA targets with potential therapeutic or prognostic value in cancer\",\"authors\":\"Matjaz Rokavec ,&nbsp;Heiko Hermeking\",\"doi\":\"10.1016/j.neo.2025.101202\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>miRTARGET (<span><span>https://www.mirtarget.com</span><svg><path></path></svg></span>) is a web tool for the identification of miRNA targets. It integrates experimental miRNA-related datasets and computational algorithms to generate prediction scores for targets of 1744 human miRNAs. The score is based on four dataset categories: mRNA profiling in cells or mice after (1) ectopic miRNA expression or (2) miRNA inactivation by knock-out or knock-down, (3) correlation analyses of mRNA and miRNA expression profiles, and (4) ten computational miRNA target prediction algorithms. Our validation analyses demonstrated a significant enrichment of published/validated miRNA targets among the predicted miRNA targets, underlining the reliability of the miRTARGET prediction score. In addition, miRTARGET integrates cancer-related datasets from primary tumors and cell lines, allowing users to filter/extract miRNA targets based on cancer cell line dependency, survival associations, and differential expression between tumor and normal tissues across 32 cancer entities. As a proof-of-concept, miRTARGET identified <em>CDC7</em> and its regulatory unit <em>DBF4</em> as the top cancer-associated predicted targets of the tumor suppressive miRNA miR-30a. Therefore, the CDC7-DBF4 complex may represent an attractive candidate therapeutic target for the treatment of cancers with miR-30a inactivation. Altogether, miRTARGET is a powerful and user-friendly web tool for exploring miRNA targets with therapeutic or prognostic potential in cancer.</div></div>\",\"PeriodicalId\":18917,\"journal\":{\"name\":\"Neoplasia\",\"volume\":\"67 \",\"pages\":\"Article 101202\"},\"PeriodicalIF\":7.7000,\"publicationDate\":\"2025-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neoplasia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S147655862500082X\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neoplasia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S147655862500082X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

miRTARGET (https://www.mirtarget.com)是一个用于识别miRNA靶点的网络工具。它整合了实验mirna相关数据集和计算算法,生成了1744个人类mirna靶点的预测分数。该评分基于四个数据集类别:细胞或小鼠在(1)异位miRNA表达或(2)敲除或敲除miRNA失活后的mRNA谱,(3)mRNA和miRNA表达谱的相关性分析,以及(4)10种计算miRNA靶标预测算法。我们的验证分析显示,在预测的miRNA靶标中,已发表/验证的miRNA靶标显著富集,强调了miRTARGET预测评分的可靠性。此外,miRTARGET整合了来自原发肿瘤和细胞系的癌症相关数据集,允许用户根据癌细胞系依赖性、生存关联以及32种癌症实体中肿瘤和正常组织之间的差异表达筛选/提取miRNA靶点。作为概念验证,miRTARGET确定CDC7及其调控单元DBF4是肿瘤抑制miRNA miR-30a的首要癌症相关预测靶标。因此,CDC7-DBF4复合物可能是治疗miR-30a失活癌症的一个有吸引力的候选治疗靶点。总之,miRTARGET是一个功能强大且用户友好的网络工具,用于探索具有治疗或预后潜力的癌症miRNA靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

miRTARGET: An integrated web tool for the identification of microRNA targets with potential therapeutic or prognostic value in cancer

miRTARGET: An integrated web tool for the identification of microRNA targets with potential therapeutic or prognostic value in cancer
miRTARGET (https://www.mirtarget.com) is a web tool for the identification of miRNA targets. It integrates experimental miRNA-related datasets and computational algorithms to generate prediction scores for targets of 1744 human miRNAs. The score is based on four dataset categories: mRNA profiling in cells or mice after (1) ectopic miRNA expression or (2) miRNA inactivation by knock-out or knock-down, (3) correlation analyses of mRNA and miRNA expression profiles, and (4) ten computational miRNA target prediction algorithms. Our validation analyses demonstrated a significant enrichment of published/validated miRNA targets among the predicted miRNA targets, underlining the reliability of the miRTARGET prediction score. In addition, miRTARGET integrates cancer-related datasets from primary tumors and cell lines, allowing users to filter/extract miRNA targets based on cancer cell line dependency, survival associations, and differential expression between tumor and normal tissues across 32 cancer entities. As a proof-of-concept, miRTARGET identified CDC7 and its regulatory unit DBF4 as the top cancer-associated predicted targets of the tumor suppressive miRNA miR-30a. Therefore, the CDC7-DBF4 complex may represent an attractive candidate therapeutic target for the treatment of cancers with miR-30a inactivation. Altogether, miRTARGET is a powerful and user-friendly web tool for exploring miRNA targets with therapeutic or prognostic potential in cancer.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Neoplasia
Neoplasia 医学-肿瘤学
CiteScore
9.20
自引率
2.10%
发文量
82
审稿时长
26 days
期刊介绍: Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信